Clinical Trial: A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)

U.S., Nov. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07253259) titled 'A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)' on Nov. 19.

Brief Summary: The goal of this clinical study is to evaluate the safety and efficacy of GT729 universal cell injection in the treatment of refractory or relapsed chronic graft-versus-host disease (cGVHD).

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: cGVHD

Intervention: BIOLOGICAL: GT729 Injection

GT729 Injection

Recruitment Status: RECRUITING

Sponsor: Grit Biotechnology

Disclaimer: Curated by HT Syndication....